Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.54 |
| ▸ | FPR2 | P25090 | 3/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 4/20 | 0.53 |
| ▸ | MMP9 | P14780 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7890615 | 1.00 | MME (0.57) | MMENPSR1CYP1A2NAALAD2FPR2 | |
| SCHEMBL436655 | 1.00 | MME (0.57) | MMENPSR1CYP1A2NAALAD2FPR2 | |
| SCHEMBL438205 | 1.00 | MME (0.57) | MMENPSR1CYP1A2NAALAD2FPR2 | |
| SCHEMBL4603054 | 0.86 | CYP1A2 (0.48) | MMENPSR1CYP1A2NAALAD2FPR2 | |
| SCHEMBL55971 | 0.85 | FOLH1 (0.56) | MMENAALAD2FOLH1L3MBTL1 | |
| SCHEMBL26993397 | 0.85 | EPHX1 (0.53) | MMENPSR1CYP1A2MMP2L3MBTL1 | |
| SCHEMBL55972 | 0.85 | FOLH1 (0.56) | MMENAALAD2FOLH1L3MBTL1 | |
| SCHEMBL8745399 | 0.85 | FPR2 (0.55) | MMENPSR1CYP1A2NAALAD2FPR2 | |
| SCHEMBL3105902 | 0.85 | FOLH1 (0.56) | MMENAALAD2FOLH1L3MBTL1 | |
| SCHEMBL9068541 | 0.83 | MME (0.70) | MMENPSR1CYP1A2NAALAD2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 812 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250345488-A1 | CROSSLINKED HYDROGELS WITH ENHANCED RADIOPACITY FOR MEDICAL APPLICATIONS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2025-11-13 | — | — | US | claimed |
| WO-2024163598-A2 | PEPTIDES COMPRISING THIOESTER GROUPS, INCLUDING DEPSIPEPTIDE THIOESTERS, METHODS OF MAKING, AND USE THEREOF | BRANDEIS UNIVERSITY (US) | 2024-08-08 | — | — | WO | claimed |
| CN-118344390-A | Polyboronate substituted phenylalanine derivative and preparation method and application thereof | 莆田兰海核医学研究中心 | 2024-07-16 | — | — | CN | claimed |
| EP-4347799-A1 | MICROORGANISMS AND USES THEREOF | United Kingdom Research and Innovation (GB) | 2024-04-10 | — | — | EP | claimed |
| EP-4161581-A1 | BISPECIFIC ANTIBODY-DRUG CONJUGATES TARGETING EGFR AND MUC1 AND USES THEREOF | Merck Patent GmbH (DE) | 2023-04-12 | — | — | EP | claimed |
| EP-4139340-A1 | HUMAN INTERLEUKIN-2 CONJUGATES BIASED FOR THE INTERLEUKIN-2 RECEPTOR BETA GAMMAC DIMER AND CONJUGATED TO A NONPEPTIDIC, WATER-SOLUBLE POLYMER | Merck Sharp & Dohme LLC (US) | 2023-03-01 | — | — | EP | claimed |
| WO-2022248061-A1 | MICROORGANISMS AND USES THEREOF | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2022-12-01 | — | — | WO | claimed |
| CN-114746099-A | Eukaryotic semisynthetic organisms | 斯克利普斯研究所 | 2022-07-12 | — | — | CN | claimed |
| EP-3923991-A1 | COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES | Ambrx, Inc. (US) | 2021-12-22 | — | — | EP | claimed |
| WO-2021216478-A1 | HUMAN INTERLEUKIN-2 CONJUGATES BIASED FOR THE INTERLEUKIN-2 RECEPTOR BETA GAMMAc DIMER AND CONJUGATED TO A NONPEPTIDIC, WATER-SOLUBLE POLYMER | MERCK SHARP & DOHME CORP. (US) | 2021-10-28 | — | — | WO | claimed |
| CN-101238143-A | Incorporation of non-naturally encoded amino acids into proteins | AMBRX INC (US) | 2008-08-06 | — | — | CN | claimed |
| CN-101223272-A | Expanding the eukaryotic genetic code | SCRIPPS RESEARCH INST (US) | 2008-07-16 | — | — | CN | claimed |
| WO-2008073184-A2 | GENETIC INCORPORATION OF UNNATURAL AMINO ACIDS INTO PROTEINS IN MAMMALIAN CELLS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-06-19 | — | — | WO | claimed |
| US-20080066741-A1 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | HUNTER, CHARLES ERIC | 2008-03-20 | — | — | US | claimed |
| WO-2007079953-A2 | IN VITRO METHOD TO PREDICT THE TUMOR SENSITIVITY TO PHARMACOTHERAPY AND ENDORADIOTHERAPY | SAMNICK SAMUEL (DE) | 2007-07-19 | — | — | WO | claimed |
| US-20070128108-A1 | Therapy of malignant neoplasias | SAMNICK SAMUEL | 2007-06-07 | — | — | US | claimed |
| WO-2007060012-A2 | USE OF L-PHENYLALANINE CONJUGATED TO AN EMITTING ISOTOPE FOR THERAPY OF HORMONE DEPENDENT CARCINOMA | SAMNICK SAMUEL (DE) | 2007-05-31 | — | — | WO | claimed |
| US-20010018042-A1 | Attaching a biocompatible lipid avid agent to a lipid accumulation in a wall of the artery; predicting rupture; atherosclerosis diagnosis | MEDIVAS, L.L.C. | 2001-08-30 | — | — | US | claimed |
| US-6232305-B1 | ANTICANCER AGENTS; BONE DISORDERS; ANTIARTHRITIC AGENTS; RESPIRATORY SYSTEM DISORDERS | NAEJA PHARMACEUTICAL INC. (CA) | 2001-05-15 | — | — | US | claimed |
| WO-2000033891-A1 | METHODS FOR DETECTION OF VULNERABLE PLAQUES USING A DETECTABLE LIPID-AVID AGENT | MEDIVAS, LLC (US) | 2000-06-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070128108-A1 | Therapy of malignant neoplasias | VHL, PAH, FAP | MME 391/4885NPSR1 1272/4885CYP1A2 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.